NEW YORK, Aug. 6, 2020 /PRNewswire/ -- Health Sciences
Acquisitions Corporation 2 (Nasdaq: HSAQ, the "Company" or "HSAC
2") announced today that it closed its initial public offering of
16,000,000 ordinary shares, which included the full exercise of the
underwriters' over-allotment option. The ordinary shares were
sold at $10.00 per ordinary share,
resulting in total gross proceeds of $160,000,000.
Health Sciences Acquisitions Corporation 2 is a blank check
company formed for the purpose of effecting a merger, share
exchange, asset acquisition, share purchase, reorganization or
similar business combination with one or more businesses. The
sponsor of the Company is HSAC 2 Holdings, LLC, an affiliate of RTW
Investments, LP. HSAC 2 anticipates targeting companies domiciled
in North America or Europe that are developing assets in the
biopharmaceutical and medical technology sectors, which aligns with
the Company's management team's experience in healthcare investing
and drug development. The Company is led by Chairman and CEO
Roderick Wong, MD and CFO
Naveen Yalamanchi, MD.
The ordinary shares began trading on The Nasdaq Capital Market
("Nasdaq") under the ticker symbol "HSAQ" on August 4, 2020.
Chardan and Barclays acted as joint book running managers in the
offering.
Loeb & Loeb LLP acted as counsel to the Company and Kirkland
& Ellis LLP acted as counsel to the underwriters.
A registration statement relating to these securities was
declared effective by the Securities and Exchange Commission on
August 3, 2020. The offering is being
made only by means of a prospectus, copies of which may be obtained
by contacting Chardan Capital Markets, LLC, 17 State Street, 21st
floor, New York, New York 10004.
Copies of the registration statement can be accessed through the
SEC's website at www.sec.gov.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
Forward Looking Statements
This press release includes forward-looking statements that
involve risks and uncertainties. Forward-looking statements are
statements that are not historical facts. Such forward-looking
statements, including the successful consummation of the Company's
initial public offering, are subject to risks and uncertainties,
which could cause actual results to differ from the forward-looking
statements. The Company expressly disclaims any obligations or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in the Company's expectations with respect thereto or any change in
events, conditions or circumstances on which any statement is
based.
Contact
Stephanie A.
Sirota
Vice President of Corporate Strategy and Corporate Communications
of HSAC 2
HSAC2@rtwfunds.com
View original
content:http://www.prnewswire.com/news-releases/health-sciences-acquisitions-corporation-2-announces-closing-of-upsized-160-million-initial-public-offering-including-full-exercise-of-the-underwriters-over-allotment-option-301107915.html
SOURCE Health Sciences Acquisitions Corporation 2